Xencor, Inc. Announces Completion of Public Offering of Common Stock and Exercise in Full of Option to Purchase Additional Shares of Common Stock

MONROVIA, Calif., March 2, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR) today announced the completion of an underwritten public offering of 8,625,000 shares of its common stock, including 1,125,000 shares sold pursuant to the full exercise of an option previously granted to the underwriters to purchase additional shares of common stock.  All of the shares were offered by Xencor at a price to the public of $14.25 per share. The gross proceeds to Xencor from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xencor, were approximately $122.9 million.  Xencor anticipates using the net proceeds from the offering for general corporate purposes, which may include clinical development of its lead drug candidates, product candidate discovery, technology development, patent prosecution activities, working capital and other general corporate purposes.

Leerink Partners acted as sole book-running manager in the offering. Wedbush PacGrow Life Sciences and Oppenheimer & Co. acted as co-managers in the offering.

The shares of common stock described above were offered by Xencor pursuant to a shelf registration statement filed by Xencor with the Securities and Exchange Commission ("SEC") that was declared effective on January 23, 2015. A final prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC's website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by email at [email protected] or by telephone at (800) 8087525.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Investor Contact:
Xencor, Inc.
John Kuch, Vice President Finance, Xencor
Tel: 626-737-8013
[email protected]

Corporate Communications Contact:
Jason I. Spark
Canale Communications for Xencor
619-849-6005
[email protected]

SOURCE Xencor, Inc.

Related Links

http://www.xencor.com/